Case report of successful treatment of fibrosing cholestatic hepatitis c with sofosbuvir and ribavirin after liver transplantation

Brian Kim, Anshu Trivedi, Swan N. Thung, Priya Grewal

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Fibrosing cholestatic hepatitis is an unusual complication of hepatitis C virus (HCV) recurrence after liver transplant. Fibrosing cholestatic hepatitis is marked by aggressive progression of cholestasis and fibrosis, leading to accelerated graft loss and/or death. Sofosbuvir (GS-7977) is an oral nucleotide analogue inhibitor of HCV polymerase activity. It is a second-generation, direct-acting, antiviral for the treatment of HCV infection. This case illustrates a patient with recurrent HCV with fibrosing cholestatic hepatitis, who was successfully treated with a combination of sofosbuvir and ribavirin with normalization of liver enzyme activities and resolution of HCV-related symptoms. The favorable side effect profile and the lack of drug-drug interaction with immunosuppressive medications make the combination of sofosbuvir and ribavirin a promising regimen for severe HCV recurrence.

Original languageEnglish
Pages (from-to)108-112
Number of pages5
JournalSeminars in Liver Disease
Volume34
Issue number1
DOIs
StatePublished - Feb 2014
Externally publishedYes

Keywords

  • cholestatic variant of hepatitis C
  • fibrosing cholestatic hepatitis
  • hepatitis C virus
  • liver transplant
  • ribavirin
  • sofosbuvir

Fingerprint

Dive into the research topics of 'Case report of successful treatment of fibrosing cholestatic hepatitis c with sofosbuvir and ribavirin after liver transplantation'. Together they form a unique fingerprint.

Cite this